“…Results of transplants for these and other congenital disorders have recently been reviewed [17], Unfortunately, normal HLA-identical sibling donors are available for only about 40% of cases. While conven tional marrow grafts from related or even unrelated donors, mismatched for HLA-A or HLA-A and HLA-B haplotype, have led to immunologic reconstitution in several patients, these grafts have often been complicated by severe acute and chronic GVHD and, in some cases, Early attempts to transplant HLA-haplotype-disparate bone marrow into patients with SCID consistently either failed to engraft, or produced fatal GVHD [4,21], How ever, the few successful fully allogeneic fetal liver trans plants in patients with SCID [22][23][24] underscored what had already been well documented in animal models of marrow transplantation: that hematopoietic cells de pleted of mature T lymphocytes could reconstitute immune function in MHC-haplotype or fully mismatched recipients without risk of severe or fatal GVHD [25][26][27][28][29], In 1980, we described a technique for removing T lymphocytes from human bone marrow for transplanta tion [30], This technique, modified to facilitate treatment of large marrow volumes [31], involves selective removal of mature blood elements with soybean agglutinin (SB A); residual T lymphocytes are subsequently removed from the unagglutinated marrow fraction by differential sedi mentation of cells that form rosettes with sheep red blood 1 Supported by US PHA grants Ca-33050, Ca-08748, The Vincent Astor Foundation, and The Robert J. Kleberg and Helen C. Kleberg Foundation.…”